留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

低氧诱导因子-1的病理生理及相关药物研究进展

冯世杰,  马秀娟,  宗英,  毛煜,  张晓冬,  弓雪莲,  张晓芳,  陆国才

downloadPDF
文章导航 > 药学实践与服务  > 2014 >  32(3): 161-166
冯世杰, 马秀娟, 宗英, 毛煜, 张晓冬, 弓雪莲, 张晓芳, 陆国才. 低氧诱导因子-1的病理生理及相关药物研究进展[J]. 药学实践与服务, 2014, 32(3): 161-166. doi: 10.3969/j.issn.1006-0111.2014.03.001
引用本文: 冯世杰, 马秀娟, 宗英, 毛煜, 张晓冬, 弓雪莲, 张晓芳, 陆国才. 低氧诱导因子-1的病理生理及相关药物研究进展[J]. 药学实践与服务, 2014, 32(3): 161-166. doi: 10.3969/j.issn.1006-0111.2014.03.001
shu
FENG Shijie, MA Xiujuan, ZONG Ying, MAO Yu, ZHANG Xiaodong, GONG Xuelian, ZHANG Xiaofang, LU Guocai. Progress in pathophysiology and related drug development of hypoxia-inducible factor-1[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(3): 161-166. doi: 10.3969/j.issn.1006-0111.2014.03.001
Citation: FENG Shijie, MA Xiujuan, ZONG Ying, MAO Yu, ZHANG Xiaodong, GONG Xuelian, ZHANG Xiaofang, LU Guocai. Progress in pathophysiology and related drug development of hypoxia-inducible factor-1[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(3): 161-166. doi: 10.3969/j.issn.1006-0111.2014.03.001
shu

低氧诱导因子-1的病理生理及相关药物研究进展

doi: 10.3969/j.issn.1006-0111.2014.03.001

  • 第二军医大学卫生毒理学教研室, 上海 200433

基金项目: 科技部重大专项"重大新药创制"(2010ZXG0900X-005),上海市公共卫生重点实验室建设计划(12GWZX0501).

Progress in pathophysiology and related drug development of hypoxia-inducible factor-1

  • Department of Health Toxicology, Second Military Medical University, Shanghai 200433, China

  • 摘要: 低氧诱导因子-1(hypoxia-inducible factors, HIF-1)是介导哺乳动物和人体细胞低氧适应性反应的主要核转录因子,是专一调节氧稳态的关键物质。HIF-1对胚胎的正常发育,软骨及骨的形成等多种生理过程起保护及促进作用,也与肿瘤、糖尿病及其并发症等多种缺血低氧性疾病密切相关。HIF-1在这些疾病中的分子机制已成为目前的研究热点,笔者就HIF-1的结构特征、调控机制、生物学效用及在药物研发等方面进行综述。
    Abstract: Hypoxia-inducible factor-1 (HIF-1) is a critical nuclear transcriptional factor mediating cell adaptive response to hypoxia in mammalian and human. It is the key mediator which modulates oxygen homeostasis exclusively. In the one hand, HIF-1 can protect and promote kinds of physiological processes, such as embryo normal development, cartilage and bone formation. In the other hand, it is also involved in lots of human deceases which is caused by ischemia and hypoxia, such as tumor, diabetes and its complications. The molecular mechanisms of HIF-1 involved in these diseases have become a research hotspot and such studies will provide the new therapeutic means for these diseases, recent new drug researches have been focused on HIF-1 related signal pathway inhibitors, HIF-1 activity inhibitors, HIF-1 targeted therapy, etc.
  • [1] Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation[J]. Mol Cell Biol, 1992, 12(12): 5447-5454.
    [2] Duval E, Ieclercq S, Elissalde JM, et al. Hypoxia-inducible factor 1alpha inhibits the fibroblast like rmrkers typeⅠand type Ⅲ collagen during hypoxia-induced chondrocyte redifferentiation:hypoxia not only induces type collagen and aggrecan,but it a1so inhibits typeⅠand type Ⅲ collagen in the hypoxia-indudble factor 1alpha-dependent redifferentiation of chondrocytes[J]. Arthr Rheum, 2009, 60(10): 3038-3048.
    [3] Lee YK, Kim EJ, Lee JE, et al. Hypoxia induces connective tissue growth factor mRNA expression[J]. J Korean Med Sci, 2009, 24(Suppl): S176-S182.
    [4] Li L, Madu CO, Lu A, et al. HIF-1 alpha promotes a hypoxia-independent cell migration[J]. Open Biol J, 2010, 3(1): 8-14.
    [5] Uniacke J, Holterman CE, Lachance G, et al. An oxygen-regulated switch in the protein synthesis machinery[J]. Nature, 2012, 486(7401):126-129.
    [6] Yoon D, Ponka P, Prchal JT. Hypoxia and hematopoiesis[J]. Am J Physiol Cell Physiol, 2011, 300(6): C1215-C1223.
    [7] Saito T, Fukai A, Mabuchi A, et al. Transcriptional regulation of endochondral ossification by HIF-2alpha during skeletal growth and osteoarthritis development[J]. Nat Med, 2010, 16(6):678-686.
    [8] Pelletier J, Dayan F, Durivault J, et al. The asparaginyl hydroxylase factor-inhibiting HIF is essential for tumor growth through suppression of the p53-p21 axis[J]. Oncogene, 2012, 31(24):2989-3001.
    [9] Glotzer DJ, Zelzer E, Olsen BR. Impaired skin and hair follicle development in Runx2 deficient mice[J]. Dev Biol, 2008, 315(2): 459-473.
    [10] Yuan LB, Dong HL, Zhang HP,et al. Neuroprotective effect of orexin-A is mediated by an increase of hypoxia-inducible factor-1 activity in rat [J]. Anesthesiology, 2011, 114(2): 340-354.
    [11] Du F, Wu XM, Gong Q, et al. Hyperthermia conditioned astrocyte-cultured medium protects neurons from ischemic injury by the up-regulation of HIF-l alpha and the increased anti-apoptotic ability [J]. Eur J Pharmacol, 2011, 666(1):19-26.
    [12] Eckle T, Kehler D, Lehmann R, et al. Hypoxia-inducible factor-1 is central to cardioprotection:a new paradigm for ischemic Preconditioning[J]. Circulation, 2008, 118(2): 166-175.
    [13] Resar JR, Roguin A, Voner J. et al. Hypoxia-inducible factor-1 alpha polymorphism and coronary collaterals in patients with ischemic heart disease[J]. Chest,2005,128(2): 787-791.
    [14] Rohwer N, Dame C, Haugstelter A, et al. Hypoxia-inducible factor l alpha determines gastric cancer chemosensitivity via modulation of p53 and NF kappaB[J]. PLOS One,20l0, 5(8): e12038-e12045.
    [15] Cai Z, Zhong H, Bosch-Marce M, et al. Complete loss of ischaemic preconditioning induced cardioprotection in mice with partial deficiency of HIF-1α[J]. Cardiovas Res, 2008, 77(3): 463-470.
    [16] Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors[J].Cancer Lett, 2009, 280(2): 145-152.
    [17] Wang Y, Liu Y, Malek SN, et al. Targeting HIF-1α eliminates cancer stem cells in hematological malignancies[J].Cell Stem Cell, 2011, 8(4): 399-411.
    [18] Mak P, Leav I, Pursell B, et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading[J].Cancer Cell, 2010, 17(4):319-332.
    [19] Luo W, Hu H, Chang R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1[J].Cell, 2011, 145(5): 732-744.
    [20] Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics[J].Oncogene, 2010, 29(5): 625-634.
    [21] Rey S, Semenza GL. Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodeling[J].Cardiovase Res, 2010, 86(2): 236-242.
    [22] Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress[J].Mol Cell, 2010, 40(2): 294-309.
    [23] Shimoda LA, Semenza GL. HIF and the lung: role of hypoxia inducible factors in pulmonary development and disease[J].Respi Crit Care Med, 2011, 183(2): 152-156.
    [24] Gartner V, Eigentler TK. Pathogenesis of diabetic macro-and microangiopathy[J].Clin Nephrol, 2008, 70(1): 1-9.
    [25] Sumual S, Saad S, Tang O, et al. Differential regulation of Snail by hypoxia and hyperglycemia in human proximal tubule cells[J].Int J Biochem Cell Biol, 2010, 42(10): 1689-1697.
    [26] Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives[J].Rev Endocr Metab Disord, 2008, 9(4): 315-327.
    [27] Takiyama Y, Harumi T, Watanable J, et al. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-lα expression and oxygen metabolism[J].Diabetes, 2011, 60(3): 981-992.
    [28] Leon GF, Jill TN. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics, progression of renal disease[J].Kidney lnt, 2008, 74(7): 867-872.
    [29] Zhang H, Qian DZ, Tan YS, et al. Digoxin and other cardiac glycosides inhibit HIF-l alpha synthesis and block tumor growth[J].Proc Natl Acad Sci USA, 2008, 105(50): 19579-19586.
    [30] Hsieh AC, Liu Y, Edlind MP, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis[J].Nature,2012, 485(7396):55-61.
    [31] Wysocki PJ. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target[J].Expert Rev Mol Diagn, 2009, 9(3): 231-241.
    [32] Choi YJ, Rho JK, Lee SJ, et al. HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines[J].J Cancer Res Clin Oncol, 2009, 135(8): 1047-1053.
    [33] Kourtis N, Nikoletopoulou V, Tavernarakis N. Small heat-shock proteins protect from heat-stroke-associated neurodegeneration[J].Nature, 2012, 490(7419), 213-218.
    [34] Ruan H, Wang J,Hu L,et al. Killing of brain tumor cells by hypoxia-responsive element mediated expression of BAX[J].Neoplasia, 1999, 1(5):431-437.
  • [1] 黄凤爱, 张俊平.  肿瘤免疫检查点PD-1/PD-L1抑制剂的中药活性成分研究进展 . 药学实践与服务, 2023, 41(5): 277-283, 290. doi: 10.12206/j.issn.2097-2024.202208079
    [2] 陈帅, 李安鹏, 李星星, 赵庆杰, 邹燕.  Hippo 信号通路在器官再生过程中的作用机制研究进展 . 药学实践与服务, 2023, 41(8): 472-477. doi: 10.12206/j.issn.2097-2024.202301008
    [3] 赖彦岚, 黄爱文, 陈官旭, 陈婷婷, 赵丽君, 廖小兰, 郭秀强, 吴刚, 宋洪涛.  SGLT-2抑制剂及GLP-1受体激动剂治疗2型糖尿病的心血管获益：一项系统回顾和网状Meta分析 . 药学实践与服务, 2022, 40(4): 354-358. doi: 10.12206/j.issn.1006-0111.202109108
    [4] 叶琳岚, 贺春晖, 朱旭婷, 李霞.  苯乙双胍联合己糖激酶抑制剂诱导三阴性乳腺癌细胞凋亡 . 药学实践与服务, 2022, 40(3): 248-253. doi: 10.12206/j.issn.1006-0111.202103045
    [5] 朱天宝, 涂杰, 盛春泉, 徐德锋, 刘娜.  组蛋白去乙酰化酶抑制剂Rocilinostat的抗真菌活性研究 . 药学实践与服务, 2022, 40(1): 44-47, 65. doi: 10.12206/j.issn.1006-0111.202103008
    [6] 刘航, 赵庆杰, 徐伟.  信号转导及转录激活因子3抑制剂研究进展 . 药学实践与服务, 2021, 39(1): 4-8. doi: 10.12206/j.issn.1006-0111.202006024
    [7] 赖彦岚, 黄爱文, 张丽丽, 廖小兰, 赵丽君, 宋洪涛.  SGLT-2抑制剂和GLP-1受体激动剂的心血管安全性研究进展 . 药学实践与服务, 2020, 38(6): 496-500, 567. doi: 10.12206/j.issn.1006-0111.202006061
    [8] 罗川, 喻支梁, 张万年, 缪震元.  非核苷类NEDD8活化酶抑制剂的设计、合成与活性研究 . 药学实践与服务, 2020, 38(1): 35-41. doi: 10.3969/j.issn.1006-0111.201901012
    [9] 姚争光, 王志斌, 夏春年, 庄春林.  冠状病毒小分子抑制剂研究进展 . 药学实践与服务, 2020, 38(5): 385-397. doi: 10.12206/j.issn.1006-0111.202005020
    [10] 姜艳娟, 崔俐俊, 贺潇蒙, 刘娜, 盛春泉.  (1,3)-β-D-葡聚糖合成酶小分子抑制剂药效团模型的构建 . 药学实践与服务, 2018, 36(2): 116-120. doi: 10.3969/j.issn.1006-0111.2018.02.005
    [11] 薛晓拉, 田泾.  质子泵抑制剂疑致肝损害1例 . 药学实践与服务, 2017, 35(5): 479-480. doi: 10.3969/j.issn.1006-0111.2017.05.024
    [12] 李翔, 邹燕, 吴茂诚, 黄婷, 胡宏岗, 吴秋业.  P53-MDM2界面的肽类及拟肽类抑制剂的研究进展 . 药学实践与服务, 2015, 33(6): 494-497,512. doi: 10.3969/j.issn.1006-0111.2015.06.004
    [13] 樊永正, 陈倩倩, 刘伯石, 赵军涛, 田巍, 周有骏, 吕加国, 朱驹.  新型苯并咪唑类人顶体酶抑制剂的设计、合成及活性研究 . 药学实践与服务, 2012, 30(3): 203-206,210. doi: 10.3969/j.issn.1006-0111.2012.03.012
    [14] 丁海峰, 曹永兵, 安毛毛, 贾鑫明, 姜远英.  SGLT2抑制剂治疗糖尿病研究进展 . 药学实践与服务, 2011, 29(2): 89-92,116.
    [15] 李秋明, 李玲.  抗凝药物新焦点——Xa因子直接抑制剂利伐沙班 . 药学实践与服务, 2010, 28(1): 1-2,47.
    [16] 宁微微, 刘雪飞, 张晓梦, 郑灿辉, 盛春泉, 周有骏, 章玲, 吕加国, 朱驹.  新型喹唑啉酮类先导物的设计、合成及抑制人顶体酶活性研究 . 药学实践与服务, 2010, 28(4): 296-298,312.
    [17] 吕志良, 王甜甜, 李科.  流感、禽流感病毒及其抑制剂研究新进展 . 药学实践与服务, 2008, (6): 405-408.
    [18] 靳姝杰, 袭荣刚, 王晓波.  血管紧张素转换酶抑制剂的不良反应和禁忌症 . 药学实践与服务, 2000, (3): 166-168.
    [19] 姜诞宁, 陈金明, 张紫洞.  血管紧张素转换酶抑制剂性咳嗽 . 药学实践与服务, 1992, (1): 8-9.
    [20] 曾明, 张紫洞.  中枢神经系统抑制剂 . 药学实践与服务, 1988, (4): 16-17.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  1892
  • HTML全文浏览量:  191
  • PDF下载量:  79
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-03-19
  • 修回日期:  2013-10-18

低氧诱导因子-1的病理生理及相关药物研究进展

doi: 10.3969/j.issn.1006-0111.2014.03.001
  • 第二军医大学卫生毒理学教研室, 上海 200433
    • 基金项目:  科技部重大专项"重大新药创制"(2010ZXG0900X-005),上海市公共卫生重点实验室建设计划(12GWZX0501).
  • 收稿日期: 2013-03-19
  • 修回日期: 2013-10-18

摘要: 低氧诱导因子-1(hypoxia-inducible factors, HIF-1)是介导哺乳动物和人体细胞低氧适应性反应的主要核转录因子,是专一调节氧稳态的关键物质。HIF-1对胚胎的正常发育,软骨及骨的形成等多种生理过程起保护及促进作用,也与肿瘤、糖尿病及其并发症等多种缺血低氧性疾病密切相关。HIF-1在这些疾病中的分子机制已成为目前的研究热点,笔者就HIF-1的结构特征、调控机制、生物学效用及在药物研发等方面进行综述。

English Abstract

冯世杰, 马秀娟, 宗英, 毛煜, 张晓冬, 弓雪莲, 张晓芳, 陆国才. 低氧诱导因子-1的病理生理及相关药物研究进展[J]. 药学实践与服务, 2014, 32(3): 161-166. doi: 10.3969/j.issn.1006-0111.2014.03.001
引用本文: 冯世杰, 马秀娟, 宗英, 毛煜, 张晓冬, 弓雪莲, 张晓芳, 陆国才. 低氧诱导因子-1的病理生理及相关药物研究进展[J]. 药学实践与服务, 2014, 32(3): 161-166. doi: 10.3969/j.issn.1006-0111.2014.03.001
shu
FENG Shijie, MA Xiujuan, ZONG Ying, MAO Yu, ZHANG Xiaodong, GONG Xuelian, ZHANG Xiaofang, LU Guocai. Progress in pathophysiology and related drug development of hypoxia-inducible factor-1[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(3): 161-166. doi: 10.3969/j.issn.1006-0111.2014.03.001
Citation: FENG Shijie, MA Xiujuan, ZONG Ying, MAO Yu, ZHANG Xiaodong, GONG Xuelian, ZHANG Xiaofang, LU Guocai. Progress in pathophysiology and related drug development of hypoxia-inducible factor-1[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(3): 161-166. doi: 10.3969/j.issn.1006-0111.2014.03.001
shu

    全文HTML

参考文献 (34)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计